...
首页> 外文期刊>Biochimica et biophysica acta. Molecular basis of disease: BBA >Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome
【24h】

Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome

机译:外周血单个核细胞中的核受体表达图可鉴定患有代谢综合征的患者

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Nuclear receptors are a class of 48 ligand-activated transcription factors identified as key players of metabolic and developmental processes. Most of these receptors are potential targets for pharmacological strategies in the Metabolic Syndrome. In the present study, we analyzed changes in the mRNA expression of nuclear receptors in the peripheral blood mononuclear cells of patients with Metabolic Syndrome, in order to identify novel biomarkers of disease and candidate targets for putative therapeutical approaches. Methods and results: We enrolled thirty healthy controls (14 M:16 F) and thirty na?ve patients (16 M: 14 F; 3 criteria for Metabolic Syndrome upon Adult Treatment Panel III) without organ damage. Using quantitative real-time PCR, we assessed the expression patterns of nuclear receptors in peripheral blood mononuclear cells. 33/48 nuclear receptors were expressed in peripheral blood mononuclear cells. In patients with Metabolic Syndrome, we found a significant down-regulation of the entire PPAR, NR4A and RAR families, together with a repression of RXRα, VDR, and Rev-Erbα. Furthermore, we performed a novel statistical analysis with classification trees, which allowed us to depict a predictive core of nuclear receptor expression patterns characterizing subjects with Metabolic Syndrome. Random Forest Analysis identified NOR1 and PPARδ, which were both reduced in peripheral blood mononuclear cells and specifically in CD14+ cells (mostly monocytes), as classifiers of Metabolic Syndrome, with high specificity and sensitivity. Conclusions: Our results point to the use of PPAR and NR4A mRNA levels in the overall peripheral blood mononuclear cells as biomarkers of Metabolic Syndrome and bona fide putative targets of pharmacological therapy.
机译:背景:核受体是一类48种配体激活的转录因子,被认为是代谢和发育过程的关键参与者。这些受体中的大多数是代谢综合征中药理策略的潜在靶标。在本研究中,我们分析了代谢综合征患者外周血单个核细胞中核受体mRNA表达的变化,以鉴定疾病的新型生物标志物和推定治疗方法的候选靶标。方法和结果:我们招募了三十名健康对照者(14 M:16 F)和三十名未接受过治疗的患者(16 M:14 F;在成人治疗小组III中,代谢综合征的标准> 3)没有器官损伤。使用定量实时PCR,我们评估了外周血单核细胞中核受体的表达模式。在外周血单个核细胞中表达33/48个核受体。在代谢综合征患者中,我们发现整个PPAR,NR4A和RAR家族均显着下调,同时抑制RXRα,VDR和Rev-Erbα。此外,我们使用分类树进行了新颖的统​​计分析,这使我们能够描绘出表征代谢综合征患者的核受体表达模式的预测核心。随机森林分析鉴定了NOR1和PPARδ,它们在外周血单核细胞中,特别是在CD14 +细胞(主要是单核细胞)中均降低,是代谢综合征的分类器,具有很高的特异性和敏感性。结论:我们的研究结果表明,外周血单个核细胞中PPAR和NR4A mRNA的水平可作为代谢综合征的生物标志物和真正的药物治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号